COMP <GO>
BBIO vs MRK // GROSS PROFIT MARGIN
BridgeBio Pharma Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BBIO 4
— MRK 10
▲ GROSS PROFIT MARGIN LEADER: BBIO
LAST: $74.95 (+5.97%) • MKT CAP: $13.83B
gross-margins
95.80%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBIO VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBIO | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 95.80% | 74.80% | +21.00 | BBIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.23% | 3.42% | -6.65 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 126.30% | 1.30% | +125.00 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.19 | -4.74 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 70.2 | 56.9 | +13.31 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.92 | +0.08 | BBIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 18.4x | +14.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.83B | $361.02B | -$347.19B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBIO REV | MRK REV | BBIO GROSS % | MRK GROSS % | BBIO FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.1M | $65.01B | 95.8% | 74.8% | -$447.0M | $12.36B |
| FY 2024 | $221.9M | $64.17B | 98.3% | 76.3% | -$521.7M | $18.10B |
| FY 2023 | $9.3M | $60.12B | 44.0% | 44.0% | -$528.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBIO // BETA 1.00
MRK // BETA 0.92